- Home
- ESEA vs OCGN Comparison
ESEA vs OCGN Comparison
Compare ESEA & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | OCGN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.3M | 387.3M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ESEA | OCGN |
|---|---|---|
| Price | $60.67 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $7.00 |
| AVG Volume (30 Days) | 27.2K | ★ 3.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.05 | $35.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.30 | $0.52 |
| 52 Week High | $66.00 | $1.96 |
Technical Indicators
Market Signals| Indicator | ESEA | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 59.44 |
| Support Level | $54.75 | $1.38 |
| Resistance Level | $60.99 | $1.47 |
| Average True Range (ATR) | 2.54 | 0.09 |
| MACD | 0.58 | 0.02 |
| Stochastic Oscillator | 78.92 | 90.55 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").